journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Pharmacoeconomics & Outcomes Research

journal
https://www.readbyqxmd.com/read/28374643/the-unknown-burden-and-cost-of-celiac-disease-in-the-u-s
#1
Douglas Mogul, Yusuke Nakamura, Jaein Seo, Barri Blauvelt, John F P Bridges
Celiac disease is an autoimmune disease that results from exposure to gluten in genetically susceptible individuals and leads to a range of gastrointestinal and extraintestinal symptoms. Areas Covered: In order to evaluate the literature with respect to burden associated with celiac disease in the U.S. and identify any knowledge gaps, we performed a literature review of journal articles published between 2000-2016. We note that celiac disease is a prevalent condition associated with a significant burden of disease through its impact on morbidity, quality of life, as well as through increased costs associated with its diagnosis and management...
April 4, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28351177/direct-and-indirect-cost-of-managing-alzheimer-s-disease-and-related-dementias-in-the-united-states
#2
Arijita Deb, James Douglas Thornton, Usha Sambamoorthi, Kim Innes
Introduction Care of individuals with Alzheimer's Disease and Related Dementias (ADRD) poses special challenges. As the disease progresses, individuals with ADRD require increasing levels of medical care, caregiver support, and long-term care which can lead to substantial economic burden. Areas Covered In this expert review, we synthesized findings from studies of costs of ADRD in the United States that were published between January 2006 and February 2017, highlighted major sources of variation in costs, identified knowledge gaps and briefly outlined directions for future research and implications for policy and program planning...
March 29, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28335636/utility-values-associated-with-advanced-or-metastatic-non-small-cell-lung-cancer-data-needs-for-economic-modeling
#3
Jacqueline Brown, Keziah Cook, Kelly Adamski, Jocelyn Lau, Danielle Bargo, Sarah Breen, Anita Chawla
Cost-effectiveness analyses often inform healthcare reimbursement decisions. The preferred measure of effectiveness is the quality adjusted life year (QALY) gained, where the quality of life adjustment is measured in terms of utility. Areas Covered: We assessed the availability and variation of utility values for health states associated with advanced or metastatic non-small cell lung cancer (NSCLC) to identify values appropriate for cost-effectiveness models assessing alternative treatments. Our systematic search of six electronic databases (January 2000 to August 2015) found the current literature to be sparse in terms of utility values associated with NSCLC, identifying 27 studies...
March 24, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28330384/federal-procurement-of-unlicensed-medicines-in-brazil-findings-and-implications
#4
Cristiane Roberta Dos Santos Teodoro, André Luís Almeida Dos Reis, Brian Godman, Rosângela Caetano, Claudia Garcia Serpa Osorio-de-Castro
BACKGROUND: There are safety concerns with using unlicensed medicines across countries including Brazil. Consequently this needs to be evaluated and concerns address if pertinent. AIM: Investigate such purchases by the Brazilian Federal Government from 2004 to 2013. METHODS: Procurement data from a public-access databank that contains procurement information of the Brazilian Federal Government. Each procured item was cross-referenced to its active drug approval status in the Brazilian National Register (DOU)...
March 23, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28287008/the-value-of-open-access-and-a-patient-centric-approach-to-oral-oncolytic-utilization-in-the-treatment-of-chronic-myelogenous-leukemia-a-u-s-perspective%C3%A2
#5
Lopamudra Das, Matthew Gitlin, Lisa R Siegartel, Dinara Makenbaeva
Since the introduction of tyrosine kinase inhibitors (TKIs), the treatment of patients with chronic myelogenous leukemia (CML) has resulted in significant improvement in patient survival but at a higher pharmaceutical cost to payers. The recent introduction of generic imatinib presents an opportunity to lower pharmacy costs within a population that is growing due to improved survival. Recent literature has focused on the likely benefits to payers of step therapy through generic imatinib. Areas covered: This review provides a perspective that is broader than the evaluation of financial savings or narrowly defined health economic metrics by incorporating factors such as CML patient heterogeneity, including varying levels of disease progression risk, comorbidities and genetic mutation status, differences in TKI product profiles, clinical guideline recommendations, and the importance of individualized patient care...
March 22, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28283002/losing-a-foot-versus-losing-a-dollar-a-systematic-review-of-cost-studies-in-diabetic-foot-complications
#6
Ioannis Petrakis, Ilias J Kyriopoulos, Alexandros Ginis, Kostas Athanasakis
Diabetes mellitus is a chronic disease with high prevalence worldwide and a range of serious related complications. Amongst them, diabetic foot is one of the most disabling, posing a substantial health and economic burden on patients and healthcare systems. Areas covered: According to projections, the expected lower limb morbidity is about to increase - in this light the present review aimed at identifying cost-of-illness studies on the management and treatment of conditions related to the diabetic foot, in an aim to provide a body of evidence for an increasing health care burden...
March 17, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28277854/economic-analysis-of-the-phase-iii-mensa-study-evaluating-mepolizumab-for-severe-asthma-with-eosinophilic-phenotype
#7
Anirban Basu, Anand Dalal, Giorgio Walter Canonica, Mark Forshag, Steven W Yancey, Saurabh Nagar, Christopher F Bell
BACKGROUND: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). METHODS: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization...
March 17, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28277852/the-treatment-patterns-of-castration-resistant-prostate-cancer-in-japan-including-symptomatic-skeletal-events-and-associated-treatment-and-healthcare-resource-use
#8
Hiroji Uemura, Marco DiBonaventura, Ed Wang, Dianne Athene Ledesma, Kristen Concialdi, Yasuko Aitoku
BACKGROUND: Real-world treatment patterns of bone metastatic castration-resistant prostate cancer (mCRPC) in Japan were examined, focusing on treatment patterns and resource use differences attributed to symptomatic skeletal events (SSEs). METHODS: Urologists (N=176) provided retrospective chart data for patients with mCRPC (N=445) via online surveys. Descriptive analyses and chi-square tests evaluated treatment patterns and their differences by SSE presence; generalized linear mixed models examined healthcare resource utilization differences as a function of SSEs...
March 6, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28277853/treatment-plan-comparison-in-acute-and-chronic-respiratory-tract-diseases-an-observational-study-of-doxophylline-vs-theophylline
#9
F S Mennini, P Sciattella, A Marcellusi, A Marcobelli, A Russo, A P Caputi
OBJECTIVES: To estimate the global cost related to the use of the two drugs (associated drugs, specialist visits, hospital admissions, plasma drug monitoring). METHODS: The drug prescriptions were extracted from the Information System of the Pharmaceutical Prescriptions of the Marche Region for each ATC code in the years 2008-2012 and the number of patients per year and other outcomes measure were obtained. RESULTS: 13,574 patients were treated with theophylline and 19,426 patients with doxophylline...
March 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28277855/using-lower-cost-statins-improves-outcomes-for-normal-cholesterol-non-diabetic-patients
#10
Ronen Arbel, Dan Greenberg
BACKGROUND The American College of Cardiology recommends considering initiation of cholesterol-lowering therapy in normal cholesterol adults aged 45-70, who are either diabetic or have a 10 year atherosclerotic cardiovascular disease higher than 7.5%. Although this policy was shown to be cost-effective, the multi-billion dollar budget impact may limit the adoption, diffusion and overall clinical impact of this therapy. OBJECTIVES We examined whether using a substantially lower cost statin (Simvastatin) in a much wider population, while accepting almost-as-good per-patient outcomes can provide better outcomes for the entire intended use population (IUP) under a pre-specified budget constraint...
February 21, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28133977/health-state-utility-estimates-for-health-technology-assessment-a-review-of-the-manufacturers-submissions-to-the-french-national-authority-for-health
#11
Francoise F Hamers, Salah Ghabri, Catherine Le Gales
OBJECTIVES: To review the selection and methods used for deriving health state utility (HSU) estimates included in the cost-utility analyses (CUA) submitted by manufacturers to the National Authority for Health (HAS) during the first 2 years after the introduction of the economic evaluation for price setting in France. METHODS: We reviewed all manufacturers' submissions that included a CUA and were assessed by HAS by the end of October 2015 (N=34). We reviewed the identification, selection, and methods used to estimate HSU and compared them with those recommended by HAS...
January 29, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28403729/cost-effectiveness-of-vildagliptin-for-people-with-type-2-diabetes-mellitus-in-brazil-findings-and-implications
#12
Gustavo Laine Araujo De Oliveira, Augusto Afonso Guerra Júnior, Brian Godman, Francisco de Assis Acurcio
Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context. Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems...
April 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28403728/analysis-of-the-implementation-of-a-personalized-care-model-in-diabetes-mellitus-as-an-example-of-chronic-disease-with-information-and-communication-technology-support
#13
N López-Martínez, J L Segú, J Vázquez-Castro, M Brosa, L Bohigas, M J Comellas, L Kalfhaus
Diabetes mellitus affects 13.8% of the adult population in Spain, representing some 8.2% of total Spanish health spending, which may be reduced by optimizing treatment and disease monitoring. Areas covered: This perspective article aims to evaluate the possible clinical and economic outcomes of implementing a theoretical personalized care model in diabetes supported by information and communications technology in Spain vs. conventional care. Moreover, we assessed the value of emminens® eConecta, a solution designed to support the operational implementation of this model, which enables the connection and participation of patients and health professionals, facilitates patient education, decision-making, access to information, and data analysis...
April 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28092207/healthcare-burden-of-depression-in-adults-with-arthritis
#14
REVIEW
Usha Sambamoorthi, Drishti Shah, Xiaohui Zhao
Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their families, payers, healthcare systems, and society as a whole. Areas covered: The primary objective of this review is to summarize, identify knowledge gaps and discuss the challenges in estimating the healthcare burden of depression among individuals with arthritis. Electronic literature searches were performed on PubMed, Embase, EBSCOhost, Scopus, the Cochrane Library, and Google Scholar to identify relevant studies...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28064553/granulocyte-colony-stimulating-factors-in-the-prevention-of-febrile-neutropenia-review-of-cost-effectiveness-models
#15
REVIEW
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H Lyman, Spiros Tzivelekis, Guillermo Villa, Milton C Weinstein
We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy. Areas covered: FN is a side effect of myelosuppressive chemotherapy associated with significant morbidity, mortality, and costs. The risk of FN may depend on the drugs used within a chemotherapy regimen, and an FN event may cause chemotherapy dose reductions or delays in subsequent cycles...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28043174/validation-and-calibration-of-structural-models-that-combine-information-from-multiple-sources
#16
REVIEW
Issa J Dahabreh, John B Wong, Thomas A Trikalinos
Mathematical models that attempt to capture structural relationships between their components and combine information from multiple sources are increasingly used in medicine. Areas covered: We provide an overview of methods for model validation and calibration and survey studies comparing alternative approaches. Expert commentary: Model validation entails a confrontation of models with data, background knowledge, and other models, and can inform judgments about model credibility. Calibration involves selecting parameter values to improve the agreement of model outputs with data...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27978765/a-systematic-review-and-checklist-presenting-the-main-challenges-for-health-economic-modeling-in-personalized-medicine-towards-implementing-patient-level-models
#17
REVIEW
Koen Degeling, Hendrik Koffijberg, Maarten J IJzerman
The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature. Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27935333/cost-utility-analysis-of-the-insufflation-of-warmed-humidified-carbon-dioxide-during-open-and-laparoscopic-colorectal-surgery
#18
Michelle Jenks, Matthew Taylor, Judith Shore
BACKGROUND: An evaluation was conducted to estimate the cost-effectiveness of insufflation of warmed humidified CO2 during open and laparoscopic colorectal surgery compared with usual care from a UK NHS perspective. METHODS: Decision analytic models were developed for open and laparoscopic surgery. Incremental costs per quality-adjusted life year (QALY) were estimated. The open surgery model used data on the incidence of intra-operative hypothermia and applied risks of complications for hypothermia and normothermia...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27927059/illness-perceptions-and-burden-of-disease-in-fibromyalgia
#19
REVIEW
Tracy L Skaer, Winghan Jacqueline Kwong
Fibromyalgia (FM) is a chronic syndrome that usually develops midlife. It is associated with a high burden of illness that causes significant disability. Areas covered: Diagnosis can be challenging, given the diverse clinical presentation among those with FM. Therefore, the typical health care journey for a patient with FM is lengthy and complex. There is no acknowledged treatment algorithm for FM, prescribing patterns vary markedly, and patients are likely to receive suboptimal or inappropriate pharmacotherapy...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27830967/the-european-society-for-medical-oncology-magnitude-of-clinical-benefit-scale-esmo-mcbs-applied-to-pivotal-phase-iii-randomized-controlled-trials-of-tyrosine-kinase-inhibitors-in-first-line-for-advanced-non-small-cell-lung-cancer-with-activating-epidermal-growth
#20
Jacopo Giuliani, Andrea Remo, Andrea Bonetti
To examine the magnitude of the clinical benefit from first-line tyrosine kinase inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)-mutations. Areas covered: The present evaluation was restricted to pivotal phase III RCTs in first-line for advanced NSCLC with activating EGFR-mutations. We have subsequently applied the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to the above pivotal phase III RCTs, to derive a relative ranking of the magnitude of clinically meaningful benefit...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
journal
journal
39911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"